The effects of smoking and its cessation on 8-epi-PGF2α and transforming growth factor-beta 1 in Type 1 diabetes mellitus

被引:19
作者
Flores, L
Vidal, M
Abian, J
Cases, A
Campistol, JM
Clària, J
Lario, S
Esmatjes, E
机构
[1] Univ Barcelona, Hosp Clin, IDIBAPS, Endocrinol & Diabet Dept,Diabet Unit, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin, IDIBAPS, Hormonal Lab, E-08036 Barcelona, Spain
[3] Univ Barcelona, Hosp Clin, IDIBAPS, Renal Transplant Unit, E-08036 Barcelona, Spain
[4] Univ Barcelona, Hosp Clin, IDIBAPS, Dialysis Unit, E-08036 Barcelona, Spain
[5] Univ Barcelona, Hosp Clin, IDIBAPS, IIBB CSIC,Struct & Biol Mass Spectrometry Unit, E-08036 Barcelona, Spain
[6] Univ Barcelona, Hosp Clin, IDIBAPS, DNA Unit, E-08036 Barcelona, Spain
关键词
tobacco; diabetes mellitus; transforming growth factor beta 1; isoprostanes;
D O I
10.1111/j.1464-5491.2004.01133.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Oxidative stress and transforming growth factor-beta 1 (TGF-beta1) are associated with diabetic complications, and smoking is a risk factor. Aims This study aimed (i) to compare urinary 8-epi-PGF2alpha and plasma and urinary TGF-beta1 levels obtained in heavy smokers with Type 1 diabetes with those observed in age-matched non-smoker patients with Type 1 diabetes and controls, and (ii) to investigate the effects of smoking cessation (SC) on the above-mentioned parameters in patients with Type 1 diabetes. Methods and results Compared with control subjects (n = 12), non-smoker diabetic patients (n = 12) presented higher values of urinary 8-epi-PGF2alpha (74.2 +/- 29.6 vs. 29.6 +/- 11.1 pg/mg urinary creatinine, P = 0.01), plasma TGF-beta1 (7.7 +/- 4.7 vs. 3.6 +/- 1.7 ng/ml, P = 0.001) and urinary TGF-beta1 (15.3 +/- 6.3 vs. 8.1 +/- 4.4 ng/mg urinary creatinine, P = 0.02). Compared with non-smoker diabetic patients, smoker diabetic patients (n = 16) showed higher levels of urinary 8-epi-PGF2alpha (107.8 +/- 40.2 vs. 74.2 +/- 29.6 pg/mg urinary creatinine, P = 0.0001), plasma TGF-beta1 (12.6 +/- 4.9 vs. 7.7 +/- 4.7 ng/ml, P = 0.001) and urinary TGF-beta1 (27.5 +/- 16.0 vs. 15.3 +/- 6.3 ng/mg urinary creatinine, P = 0.01). Smoker patients were included in a smoking cessation programme. In the 10 patients that gave up smoking there was a reduction of urinary 8-epi-PGF2alpha (basal: 110.47 +/- 47.0 vs. week 12: 73.2 +/- 25.6; P < 0.001), plasma TGF-beta1 (basal: 11.2 +/- 5.9 vs. week 12: 4.89 +/- 2.25; P < 0.01) and urinary TGF-beta1 (basal: 18.12 +/- 9.27 vs. week 12: 10.32 +/- 2.0; P < 0.01) levels. Conclusions In patients with Type 1 diabetes, smoking increased oxidative stress, evaluated by lipid peroxidation, and TGF-beta1 production. Smoking cessation decreased these parameters, providing additional support to encourage diabetic patients to give up smoking.
引用
收藏
页码:285 / 289
页数:5
相关论文
共 31 条
[1]   Role of oxidative stress in diabetic complications - A new perspective on an old paradigm [J].
Baynes, JW ;
Thorpe, SR .
DIABETES, 1999, 48 (01) :1-9
[2]   Tobacco smoke is a source of toxic reactive glycation products [J].
Cerami, C ;
Founds, H ;
Nicholl, I ;
Mitsuhashi, T ;
Giordano, D ;
Vanpatten, S ;
Lee, A ;
AlAbed, Y ;
Vlassara, H ;
Bucala, R ;
Cerami, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13915-13920
[3]  
CHURCH D, 1985, ENV HLTH PERSPECT, V96, P111
[4]  
Davì G, 1999, CIRCULATION, V99, P224
[5]  
Ellis D, 1998, CLIN CHEM, V44, P950
[6]   Smoking increases serum levels of transforming growth factor-β in diabetic patients [J].
Esmatjes, E ;
Flores, L ;
Lario, S ;
Clària, J ;
Cases, A ;
Iñigo, P ;
Campistol, JM .
DIABETES CARE, 1999, 22 (11) :1915-1916
[7]   Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM [J].
Forsblom, CM ;
Groop, PH ;
Ekstrand, A ;
Tötterman, KJ ;
Sane, T ;
Saloranta, C ;
Groop, L .
DIABETES CARE, 1998, 21 (11) :1932-1938
[8]   GAS-PHASE OXIDANTS OF CIGARETTE-SMOKE INDUCE LIPID-PEROXIDATION AND CHANGES IN LIPOPROTEIN PROPERTIES IN HUMAN BLOOD-PLASMA - PROTECTIVE EFFECTS OF ASCORBIC-ACID [J].
FREI, B ;
FORTE, TM ;
AMES, BN ;
CROSS, CE .
BIOCHEMICAL JOURNAL, 1991, 277 :133-138
[9]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[10]  
GIULIANO D, 1996, DIABETES CARE, V19, P257